Post

First patient dosed in Compass Therapeutics’ Phase Ib solid tumour trial

CTX-471 attaches to the CD137 receptor’s membrane proximal epitope, leading to improved activation of T-Cells and NK Cells.

IGC starts clinical trial of drug candidate to treat agitation in dementia

The objective of the trial is to establish IGC-AD1’s efficacy in helping dementia patients reduce neuropsychiatric symptoms.

Curebase and Redenlab to partner for data capture capabilities expansion

The analytical component provides researchers with a comprehensive monitoring approach in trials.

How to cut drug supply costs with seamless forecasting and IRT systems

Cut drug wastage, reduce risk, and optimise supply with advanced, integrated technologies designed to deliver increased visibility, flexibility and accuracy.

Petition to update US alcohol warning label could prevent many cancer cases

Individuals who are more prone to alcoholism are at an increased risk of breast and colorectal cancers.

Nimbus Therapeutics reports positive data from psoriasis therapy trial

In the study, NDI-034858 achieved statistical significance in a greater number of patients, with more reaching PASI-75.

ISA concludes subject enrolment in HPV16 positive OPC therapy trial

The trial will assess ISA101b’s safety and efficacy in HPV16 positive OPC patients.

Clarametyx launches Phase Ia bacterial pneumonia antibody trial

The trial launch is backed by various preclinical studies, where CMTX-101 showed anti-biofilm activity.

Nectin doses first subject in Phase I solid tumour immunotherapy trial

A monoclonal antibody, NTX1088 is directed against a transmembrane protein called PVR.

Just announced: upcoming HIV late-stage clinical trials

Clinical Trials Arena examines recently announced Phase III studies in the HIV therapeutic landscape.

UCI Health and UCI Alpha Clinic launch muscle atrophy therapy trial

The trial will assess IMM01-STEM’s tolerability and safety in patients with muscle atrophy.

NETRIS Pharma begins subject dosing in solid tumour therapy trial

The trial will assess the biological and clinical activity of NP137 as an add-on therapy in solid tumours patients.

Intravacc enrols first subject in intranasal Covid-19 booster trial

The initial interim data from the trial is anticipated by the end of the first quarter of next year.

Friedreich’s ataxia: major trial readouts and regulatory events to watch in 2023

The FDA could approve the first treatment for Friedreich’s ataxia, and at least three other major trials have readouts expected by year end.

Autobahn begins dosing in Phase I major depressive disorder treatment trial

An oral TRβ agonist, ABX-002 had shown target engagement in areas of the brain linked to depression.